← All trials
NCT04357457
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2020
- Primary completion
- Jul 31, 2020
- Completion date
- Jul 31, 2020
- First posted
- Apr 22, 2020
- Last posted
- May 13, 2020
- Enrollment
- 212
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Assistance Publique - Hôpitaux de ParisLead sponsor
- Assistance Publique - Hôpitaux de ParisOverall official - principal investigator
- Centre Hospitalier of ChartresCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.